Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00097383 | Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer | PHASE1 | COMPLETED | - | — | — | - | - | Jul 19, 2006 | 25 | Argentina, Belgium +3 |
| Name | Type | Description |
|---|---|---|
| ALIMTA plus Epirubicin | DRUG | - |
Inclusion Criteria: * Diagnosis of locally advanced or metastatic breast cancer not amenable to local treatment. * Patients must be chemo-naive or have only neoadjuvant and/or adjuvant chemotherapy. * Patients must have at least one measurable lesion in an area not previously irradiated. * No chemo...